GlassScriptPhysician profile
Joseph Valayam
NPI 1770817124
$7,096.41
in general payments reported to CMS, 2019-2025
37 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,026 · 2020: $596 · 2021: $813 · 2022: $969 · 2023: $1,136 · 2024: $893 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,305.40 | 2019-2023 | Pressurewire |
| Novartis Pharmaceuticals Corporation | $875.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $826.58 | 2019-2024 | Wainua, Farxiga, Brilinta |
| Amgen INC. | $616.03 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $488.90 | 2019-2022 | |
| Pfizer INC. | $314.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $308.65 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $279.39 | 2019-2024 | Lifevest |
| Irhythm Technologies, INC. | $242.77 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $199.49 | 2021-2024 | |
| Chiesi USA, INC. | $194.41 | 2019-2025 | Kengreal, Cleviprex |
| Actelion Pharmaceuticals US, INC. | $191.18 | 2019-2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $151.83 | 2021-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $127.91 | 2021-2025 | Bodyguardian |
| Astellas Pharma US INC | $97.02 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elutia, INC. | $85.08 | 2020-2023 | |
| Penumbra, INC. | $75.75 | 2021 | |
| Teleflex LLC | $66.98 | 2024 | Turnpike |
| Sanofi-Aventis U.S. LLC | $66.93 | 2021-2024 | |
| Cardiovascular Systems INC. | $64.93 | 2020 | |
| Amarin Pharma, INC. | $57.05 | 2019-2021 | |
| Novo Nordisk INC | $55.98 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $53.80 | 2021-2022 | |
| Philips North America LLC | $53.19 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.89 | 2021-2022 | |
| Scpharmaceuticals INC. | $38.45 | 2025 | |
| Alnylam Pharmaceuticals INC. | $36.40 | 2024-2025 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $33.29 | 2021-2022 | |
| Portola Pharmaceuticals, LLC | $25.82 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $21.93 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $18.58 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.94 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.03 | 2019 | |
| Lundbeck LLC | $13.48 | 2019 | |
| Genzyme Corporation | $13.42 | 2019 | |
| Vifor Pharma, INC. | $11.07 | 2019 | |
| Inogen, INC. | $7.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Valayam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.